BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou Biopharmaceuticals Co., Ltd. The collaboration aims to harness their combined expertise in generative AI technology for target discovery, with the goal of developing IND-stage drugs and creating an advanced AIGC-driven antibody drug discovery platform.
The partnership will leverage BioGeometry’s proprietary generative AI antibody design platform, GeoBiologics, while Sanyou will provide its resources, technical expertise, and industry experience. By integrating BioGeometry’s cutting-edge AI algorithms with Sanyou’s wet lab capabilities, the two firms aim to establish a high-performance antibody research and development platform. This initiative will focus on advancing macromolecular drug candidates and incubating innovative projects in the biotechnology sector.- Flcube.com
